Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — Sosei Group — Jefferies London Healthcare Conference 2021
23 slides from Nxera Pharma's conference presentation, Nov 16, 2021
Slide 1: World leading drug discovery targeting GPCRs
NON – CONFIDENTIAL World leading drug discovery targeting GPCRs Corporate Presentation 2021 | © Sosei Group Corporation
Slide 2: Disclaimer
Disclaimer The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed
Slide 3: World leading drug discovery targeting GPCRs
World leading drug discovery targeting GPCRs World leader in EVOLVING WITH A SPECIALIST GPCR drug discovery THERAPEUTIC FOCUS and early development Advancing a broad and deep Proprietary GPCR-targeted pipeline of over 40 partnered StaR® technology and SBDD and in-house programs across platform capab
Slide 4: We can unlock the potential of GPCRs with our StaR technology
We can unlock the potential of GPCRs with our StaR® technology GPCRs are well-known targets with StaR® enables us to unlock the potential of GPCRs via advanced significant untapped opportunity understanding of their structure and atomic/molecular interactions Unstable ~400 native GPCR GPCR PROTEINS
Slide 5: Core capabilities in drug discovery and early development, with a late-stage development team in Japan
Core capabilities in drug discovery and early development, with a late-stage development team in Japan focused on in-licensing DRUG DISCOVERY/EARLY DEVELOPMENT DRIVEN BY STAR® / SBDD ENGINE LATE STAGE DEVELOPMENT PRE-DISCOVERY DISCOVERY PRECLINICAL PH 1a PH 1b PH 2/3 APPROVAL StaR® Technology SBDD D
Slide 6: Established track record of attracting world-leading partners
Established track record of attracting world-leading partners Active Partnerships Active Spin-Out Asset Centric Vehicles ~$700 ~$6 Upfront and milestone payments, royalties and R&D funding Total potential deal value of active partnerships2 million received from partners to date1 billion 1 Encompasse
Slide 7: Ten drug candidates generated from our SBDD platform have been advanced into clinical trials
Ten drug candidates generated from our SBDD platform have been successfully advanced into clinical trials TODAY* Generated 25 LEAD OP preclinical 6 programs Acquisition of Heptares candidates by Sosei PRECLINICAL Produced 9 candidates 10 CLINICAL clinical candidates 9 candidates One of the most prod
Slide 8: Progress in collaborative drug discovery, three new major partnerships over the past year
We are continuing to make progress in collaborative drug discovery, having added three new major partnerships over the past year… Partner Active Partnered Program Therapeutic Area UF / Near Term Payments Potential deal value1 2020 Collaboration and Licensing Gastrointestinal, $44m $480m+ Agreement f
Slide 9: Deep pipeline of in-house programs, plus new technology collaborations
…and a deep pipeline of exciting in-house programs, plus new technology collaborations, that will form the partnerships of the future Pre-Disc. / Discovery Preclinical studies Phase 1 Phase 2 Marketed Multi-target GPR35 ag. GLP-1 ag. A2a ant. combo(s)** Ultibro® Breezhaler® Multiple IBD T2DM/Obesity
Slide 10: Next wave of COVID-19 therapies – SARS-CoV-2 protease inhibitors
Next wave of COVID-19 therapies – SARS-CoV-2 protease inhibitors PAXLOVID™ (PF-07321332; ritonavir) S-217622 – small molecule oral SH-879 – small molecule oral antiviral – small molecule oral antiviral antiviral treatment; once a day treatment; once or twice daily dosing Overview treatment; twice a
Slide 11: Muscarinic portfolio, led by HTL'878, represents a ready-made neuroscience pipeline
Muscarinic portfolio, led by HTL’878, represents a ready-made HTL’878 neuroscience pipeline of multiple potential blockbuster programs Next Milestone Program Compound Indication Discovery Preclinical Phase 1 Phase 2 12-18 months HTL’878 Schizophrenia Phase 2 ready M4R ortho agonist Completion of ort
Slide 12: HTL'878 is a 4th-generation candidate for a safer treatment for Schizophrenia
HTL’878 is a 4th-generation candidate aiming to be a highly HTL’878 effective and safer treatment for Schizophrenia Efficacy Safety Positive Negative Cognitive Extrapyramidal Weight gain symptoms symptom impairment symptoms** Peak sales Number of patients Number of patients Number of patients MoA Ty
Slide 13: HTL'878 is the only highly selective orthosteric agonist of muscarinic M4 in development
HTL’878 is differentiated and is the only highly selective HTL’878 orthosteric agonist of the muscarinic M4 receptor in development Direct agonism of • Direct agonism of the muscarinic M4 mechanism is a clinically validated target for the treatment of psychoses M4R is a clinically (Xanomeline, KarXT
Slide 14: Looking forward
Looking forward 14
Slide 15: Strategic growth plan driving corporate value expansion
Strategic growth plan driving corporate value expansion OBJECTIVE STRATEGIC GROWTH PLAN OBJECTIVE Add new technology Capital raise capabilities to our completed to pursue SBDD platform revenue focused deals in 2021/2022 Seek out revenue- Invest / collaborate in generating opportunities novel tec
Slide 16: Three big challenges in drug discovery and development
Three big challenges in drug discovery and development KEY OPPORTUNITY Choosing Discovering Conducting the right target a therapeutic agent the right patient studies • Will modulating the target • Identifying a modulator with • Demonstrating the value of affect disease? the appropriate profile the a
Slide 17: AI / Machine Learning target ID and validation framework
We have created the New target ID and validation (TIV) framework to accelerate our quest to choose the right targets To support the identification and validation of new drug GPCR targets Bioinformatics AI / Machine Learning Aim across our core therapeutic areas (GI, Proteomics immunology, immuno-onc
Slide 18: New TIV Framework - mid-term plan to pursue investments and external collaborations
New TIV Framework - mid-term plan to pursue investments and external collaborations to hunt novel first-in-class drug targets 2021 2022 2023 2024 INTERNAL THERAPEUTIC AREA INITIATIVES PRE-DISCOVERY DISCOVERY Therapeutic Area PE BMS HID H2L LO MAXIMIZE EXISTING COLLABORATIONS TV Target ID Target Va
Slide 19: Priority objectives for FY2021/FY2022
Priority objectives for FY2021/FY2022 Progress organic Execute strategic Commitment to sustainable growth plan growth plan development goals • Extend technology / platform • Invest / collaborate in novel • Promote sustainable ESG leadership technologies practices and policies across • Generate high
Slide 20: Appendix
Appendix 20
Slide 21: Progression of Partnered Pipeline
Progression of Partnered Pipeline FY2020 stage FY2021-Now progress Compound Target / Mechanism of Action Modality Indication Partner Disc. PCC Ph1 Ph2 Ph3 App Mkt Traditional Out-licensing Collaborations Seebri® Breezhaler® LAMA SME COPD Ultibro® Breezhaler® LAMA+LABA SME COPD Enerzair® Breezhaler®
Slide 22: Progression of In-house Pipeline
Progression of In-house Pipeline FY2020 stage FY2021-Now progress Compound Target / Mechanism of Action Modality Indication Originator Dis PCC Ph1 Ph2 Ph3 App Mkt. In-house Programs (Not yet partnered) HTL’878 Muscarinic M4 agonist SME Neurology diseases HTL’318 1 Muscarinic M1 agonist SME Neurology
Slide 23: Sosei Heptares
IR@soseiheptares.com SOSEI HEPTARES PMO Hanzomon 11F Steinmetz Building North West House 2-1 Kojimachi, Chiyoda-ku Granta Park, Cambridge 119 Marylebone Road Tokyo 102-0083 CB21 6DG London NW1 5PU Japan United Kingdom United Kingdom www.soseiheptares.com @soseiheptaresco @soseiheptaresco @soseihepta
Sosei Group — Jefferies London Healthcare Conference 2021 on 6ix